A human CD4 monoclonal antibody for the treatment of T cell lymphoma combines inhibition of T cell signaling by a dual mechanism with potent Fc-dependent effector activity

D.A. Rider, C.E.G. Havenith, R. de Ridder, J. Schuurman, C. Favre, J.C. Cooper, S.M. Walker, O. Baadsgaard, S. Marschner, J.G.J. van de Winkel, J. Cambier, P.W.H.I. Parren, D.R. Alexander

    Research output: Contribution to journalArticleAcademicpeer-review

    Original languageUndefined/Unknown
    Pages (from-to)9945-9953
    Number of pages9
    JournalCancer Research
    Volume67
    Publication statusPublished - 2007

    Cite this